<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474499</url>
  </required_header>
  <id_info>
    <org_study_id>FE999306 CS01</org_study_id>
    <nct_id>NCT01474499</nct_id>
  </id_info>
  <brief_title>A Trial of Docusate Sodium and Sorbitol Rectal Solution for the in Patients With Constipation</brief_title>
  <official_title>A Multi-center, Randomized, Single-blind Clinical Study of the Comparative Safety and Efficacy of Docusate Sodium and Sorbitol Rectal Solution and Glycerine Enemas in Patients With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of the docusate sodium and sorbitol
      rectal solution produced by Ferring Pharmaceutical (China) Ltd. in treating Chinese patients
      with constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall efficacy rate of the enema in treating the symptoms of constipation</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from conclusion of enema administration to patient's first bowel movement</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of straining that occurs during bowel movement (normal/difficult)</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feeling of emptying of the rectum post bowel movement (complete/incomplete)</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool form after enema treatment according to Bristol Stool Scale</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anal complaints (absent, anal itch, anal irritation or anal pain)</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal pain (absent, mild, moderate, or severe)</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's overall assessment of using the enema to treat the symptoms of constipation</measure>
    <time_frame>Up to 30 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Docusate sodium and sorbitol rectal solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycerine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerine</intervention_name>
    <arm_group_label>Glycerine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docusate sodium and sorbitol rectal solution</intervention_name>
    <arm_group_label>Docusate sodium and sorbitol rectal solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have signed the informed consent form and have been verbally told of the details of
             the trial and treatment procedures

          -  Is a citizen of the People's Republic of China

          -  Males and females aged between 18 and 65 years inclusive

          -  A history of constipation symptoms for at least 6 months, with occurrence of two or
             more of the symptoms during the 3 months before screening:

               1. More than 1/4 of stool classifiable as Type I or Type II on the Bristol Stool
                  Scale;

               2. Sensation of incomplete evacuation at least 1/4 of the time;

               3. Straining during defecation at least 1/4 of the time;

               4. Sensation of ano-rectal blockage or obstruction during defecation at least 1/4 of
                  the time;

               5. Manual manoeuvres needed often to facilitate defecations (e.g. digital
                  evacuation) at least 1/4 of the time;

               6. Fewer than 3 bowel movements per week

          -  No bowel movement within two days prior to randomisation

        Exclusion Criteria:

          -  Patients who are suspected to have colorectal cancer;

          -  Patients showing signs of bleeding in the digestive tract or inflammatory bowel
             disease;

          -  Patients experiencing abdominal discomfort or intestinal blockage for which the cause
             has yet to be determined;

          -  Patients allergic to docusate or sorbitol;

          -  Patients allergic to glycerine;

          -  Those pregnant, breastfeeding, or with the intention of becoming pregnant, or fertile
             women who are not on effective birth controlï¼ˆi.e. an IUD (intrauterine device), oral
             contraceptives or other obstructive measures;

          -  Severe liver damage (ALT (alanine aminotransferase), AST (aspartate transaminase),
             TBIL (serum total bilirubin) more than 2 times the upper limit of normal)

          -  Kidney function impairment (Cr (creatinine clearance rate), BUN (blood urea nitrogen)
             more than 1.5 times the upper limit of normal)

          -  Patients who have participated in any other clinical trial during the last 3 months;

          -  Diabetics who are currently undergoing insulin treatment;

          -  Patients who are unable to suspend using treatments that affect the kinetics of the
             digestive system in the 5 days prior randomisation. Such treatments include prokinetic
             drugs, erythromycin analogues, laxatives, etc;

          -  Other patient factor(s) (e.g. medical history, concurrent illness(es), laboratory test
             result(s), etc.) at Screening that in the opinion of the investigator(s) would put the
             trial patient at excessive risk;

          -  Patients who are unable to act in a legal capacity, unable to meet or perform study
             requirements, or are known or suspected as unable to comply with the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Medical University - Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University Medical School - Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University Medical School - Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <last_update_submitted>September 24, 2012</last_update_submitted>
  <last_update_submitted_qc>September 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Glycerol</mesh_term>
    <mesh_term>Sorbitol</mesh_term>
    <mesh_term>Bismuth subsalicylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

